Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubl...
AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and...
Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE) announced compelling five-year overall survival (OS) results from the open-label exten...
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the compa...
JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered ...
-Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi®, a recombinant DNA-derived, extended half-life factor VIII conce...
Microba Life Sciences Limited, a precision microbiome company, announces preliminary results from the analysis of over 4,600 MetaXplore™ GI P...
Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that it has e...
MaxisIT, a long-recognized provider of clinical data analytics platform for clinical trials, today announced its transformation into Maxis AI. This strat...
Demonstrated strong safety and favorable pharmacokinetics in Phase 1 study A First-in-class oral small molecule modulating immune cell metabolism vi...
UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission o...
Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer pati...
ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus standard gemcitabine/nab-paclitaxel chemotherapy had increased overall survival, progress...
© 2025 Biopharma Boardroom. All Rights Reserved.
